PIK3CA and cancer: In conclusion, our study demonstrated that the combination of alpelisib 300 mg daily and capecitabine 1,250 mg/m2 twice daily for 14 days in 3-weekly cycles is a safe and well-tolerated treatment option for patients with advanced cancers harboring PIK3CA mutations.